妊娠期随机试验参与者和非参与者的结局比较:系统综述与Meta分析
该系统综述与Meta分析检索了MEDLINE、Scopus、CINAHL、Cochrane Library和Ovid(至2022年5月),纳入17项产科随机对照试验(103,610例,其中参与者26,293例、非参与者77,317例)。结果显示,参与者的复合不良结局风险与非参与者无差异(OR 0.88,95%CI 0.52-1.49,I²=90%)。作者认为应向孕妇提供这一 reassuring 信息,并可能改善招募。
要点
- 产科随机对照试验参与者与非参与者的复合不良结局风险无差异(OR 0.88,95%CI 0.52-1.49)。
- 仅纳入报告主要结局的12项试验时,两组结局仍无差异(OR 0.76,95%CI 0.38-1.49,I²=93%)。
- 试验干预不对非参与者开放的7项试验亚组中,两组结局亦无差异(OR 0.91,95%CI 0.45-1.85,I²=68%)。
核心结论
- 同意参与随机对照试验的孕妇与拒绝参与者的结局无差异。
- 作者认为应向孕妇提供这一 reassuring 信息,并可能改善随机对照试验的患者招募。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Scopus、CINAHL、Cochrane Library和Ovid,从建库至2022年5月。
- 纳入17项报告参与者和非参与者临床结局的产科随机对照试验,共103,610例(参与者26,293例,非参与者77,317例)。
- 采用Newcastle-Ottawa量表评估偏倚风险,随机效应模型合并OR及95%CI,用I²统计量评估异质性,漏斗图检查发表偏倚。
主要发现
- 主要结局为发病的复合终点,17项试验中参与者与非参与者无差异(OR 0.88,95%CI 0.52-1.49,I²=90%)。
- 仅纳入报告主要结局的12项试验,两组仍无差异(OR 0.76,95%CI 0.38-1.49,I²=93%)。
- 试验干预不对非参与者开放的7项试验亚组中,两组无差异(OR 0.91,95%CI 0.45-1.85,I²=68%)。
- 9项研究未被评为高质量,主要因未能控制混杂因素。
- 试验干预分为产前(n=11)、产时(n=5)或产后(n=1)。
临床怎么用
- 作者认为,在邀请孕妇参与随机对照试验时,应向其提供这一 reassuring 信息。
- 作者认为,该信息可能改善随机对照试验的患者招募。
局限性
- 9项研究未被评为高质量,主要因未能控制混杂因素。
- 总体分析异质性I²=90%。
- 仅纳入报告主要结局的试验分析异质性I²=93%。
- 试验干预不对非参与者开放的亚组异质性I²=68%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to evaluate the outcomes among individuals who were eligible and approached for participation in a randomized controlled trial during pregnancy, comparing those who enrolled with those who declined participation. DATA SOURCES: MEDLINE, Scopus, CINAHL, the Cochrane Library, and Ovid were searched from study inception to May 2022. STUDY ELIGIBILITY CRITERIA: This study included all obstetrical randomized controlled trials that reported clinical outcomes for both participants and nonparticipants. METHODS: The primary outcome captured the presence of morbidity. It was a composite of the primary outcome of each study comparing the participant arm with the nonparticipant arm. If a primary outcome was not clearly defined, a surrogate was developed on the basis of the core outcomes for the clinical condition studied. The risk of bias was assessed with the Newcastle-Ottawa Scale. Subgroup analyses for relevant obstetrical and neonatal outcomes were performed. The summary comparisons were reported as odds ratios with 95% confidence intervals computed using random-effects meta-analysis with heterogeneity evaluated using the I2 statistic. A funnel plot was used to examine publication bias, and there was no asymmetry. RESULTS: After reviewing more than 1100 abstracts, 17 obstetrical randomized controlled trials (103,610, with 26,293 participants and 77,317 nonparticipants) met our inclusion criteria and were analyzed. Of note, 9 studies were not rated as high quality, primarily for failing to control for confounding factors. Trial interventions were categorized as antepartum (n=11), intrapartum (n=5), or postpartum (n=1). Overall, participants in obstetrical randomized controlled trials had no difference in outcomes compared with nonparticipants (n=17: odds ratio, 0.88; 95% confidence interval, 0.52-1.49; I2=90%). Moreover, there was no difference seen when only randomized controlled trials that reported a primary outcome were included (n=12: odds ratio, 0.76; 95% confidence interval, 0.38-0.1.49; I2=93%). In addition, there was no difference noted in the subgroup where the randomized controlled trial intervention was not available to nonparticipants (n=7: odds ratio, 0.91; 95% confidence interval, 0.45-1.85; I2=68%). CONCLUSION: Pregnant individuals who agreed to participate in randomized controlled trials had no difference in outcomes compared with those who decline participation. Pregnant individuals should be provided with this reassuring information when offered to participate in a randomized controlled trial. Moreover, this information may improve patient recruitment into randomized controlled trials.
引用
- Jayakumaran J, Angarita AM, Chauhan SP, et al. Outcomes among participants vs nonparticipants of randomized trials during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2022. PMID: 35853585. doi:10.1016/j.ajogmf.2022.100695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。